Teladoc Health
TDOC· Services· Fiscal year ends in December
Charles Divita, III is the CEO of Teladoc Health and was paid $11.2M in FY2025 (Dec), down 30%.
Executives5
See all- 1Charles Divita, IIIChief executive officerFY2025
- 2Mala MurthyFormer chief financial officerFY2025
- 3Carlos NuenoPresident, internationalFY2025
- 4Kelly BlissPresident, U.S. group healthFY2025
- 5Adam C. VandervoortChief legal officer and secretaryFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allTeladoc Health paid its 5 named executives $24.1M in total in FY2025 (Dec). CEO Charles Divita, III was paid $11.2M of that.
| Name | |||
|---|---|---|---|
| Charles Divita, IIIChief executive officer | Not disclosed | ||
| Mala MurthyFormer chief financial officer | |||
| Carlos NuenoPresident, international | Not disclosed | ||
| Kelly BlissPresident, U.S. group health | Not disclosed | ||
| Adam C. VandervoortChief legal officer and secretary |
of each named executive, from the Summary Compensation Table of each proxy.
Peers19
See allThe FY2025 (Dec) proxy of Teladoc Health names 19 peer companies for pay. Among Teladoc Health and these peers, CEO pay was 8th highest of 11 and total shareholder return was the lowest of 11.
8th highest of 11in Teladoc Health and its pay peers, FY2025 (Dec) by CEO pay:
11th highest of 11in Teladoc Health and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board1
See all- Kenneth H. PaulusChair · 8 yr on the boardIndependentCompensation, Executive (Chair), Nominating and Corporate Governance, Quality of Care and Patient Safety—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 7, 2026 | FY2025 |
| Annual report | 10-K | Feb 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 8, 2025 | FY2024 |
| Annual report | 10-K | Feb 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 9, 2024 | FY2023 |
| Annual report | 10-K | Feb 23, 2024 | FY2023 |